eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Aug 25, 2021 07:18PM
eFFECTOR Therapeutics and Locust Walk Acquisition (LWAC) Announce Merger Agreement May 27, 2021 08:02AM
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies May 27, 2021 08:00AM
Locust Walk Acquisition Corp. (LWAC) Prices 15.3M Unit Upsized IPO at $10/Unit Jan 8, 2021 05:56AM